- Home
- ADCT vs PROF Comparison
ADCT vs PROF Comparison
Compare ADCT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- PROF
- Stock Information
- Founded
- ADCT 2011
- PROF N/A
- Country
- ADCT Switzerland
- PROF Canada
- Employees
- ADCT N/A
- PROF N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- ADCT Health Care
- PROF Health Care
- Exchange
- ADCT Nasdaq
- PROF Nasdaq
- Market Cap
- ADCT 224.3M
- PROF 221.6M
- IPO Year
- ADCT 2020
- PROF N/A
- Fundamental
- Price
- ADCT $1.72
- PROF $7.25
- Analyst Decision
- ADCT Strong Buy
- PROF Strong Buy
- Analyst Count
- ADCT 5
- PROF 2
- Target Price
- ADCT $8.00
- PROF $11.40
- AVG Volume (30 Days)
- ADCT 709.5K
- PROF 70.6K
- Earning Date
- ADCT 03-12-2025
- PROF 03-06-2025
- Dividend Yield
- ADCT N/A
- PROF N/A
- EPS Growth
- ADCT N/A
- PROF N/A
- EPS
- ADCT N/A
- PROF N/A
- Revenue
- ADCT $70,717,000.00
- PROF $8,984,000.00
- Revenue This Year
- ADCT $6.81
- PROF $57.62
- Revenue Next Year
- ADCT $11.23
- PROF $160.54
- P/E Ratio
- ADCT N/A
- PROF N/A
- Revenue Growth
- ADCT N/A
- PROF 39.35
- 52 Week Low
- ADCT $1.68
- PROF $6.78
- 52 Week High
- ADCT $6.04
- PROF $11.42
- Technical
- Relative Strength Index (RSI)
- ADCT 40.45
- PROF 43.18
- Support Level
- ADCT $1.68
- PROF $7.16
- Resistance Level
- ADCT $1.87
- PROF $7.88
- Average True Range (ATR)
- ADCT 0.13
- PROF 0.34
- MACD
- ADCT 0.00
- PROF -0.01
- Stochastic Oscillator
- ADCT 8.65
- PROF 27.67
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.